BioLife Solutions (BLFS) executive sells 2,577 shares under 10b5-1 plan

Rhea-AI Filing Summary

BioLife Solutions Inc. executive Karen A. Foster sold 2,577 shares of common stock in an open-market transaction. The sale occurred at a weighted average price of $19.17 per share and was executed under a pre-arranged Rule 10b5-1(c) trading plan adopted effective December 4, 2025.

Following this transaction on March 23, 2026, Foster directly held 108,758 shares of BioLife Solutions common stock. The shares were sold in multiple trades at prices ranging from $18.99 to $19.35, and detailed breakdowns are available upon request as noted in the filing.

Insider Trade Summary 10b5-1

Net Seller: 2,577 shares ($49,401)

Net Sell 1 txn

Insider Foster Karen A.

Role Chief Quality and Operations

Sold 2,577 shs ($49K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,577	$19.17	$49K

Holdings After Transaction: Common Stock — 108,758 shares (Direct)

Footnotes (1)

1. The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 12-04-2025 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.99 to $19.35, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Shares sold: 2,577 shares Weighted average sale price: $19.17 per share Post-transaction holdings: 108,758 shares +2 more

5 metrics

Shares sold 2,577 shares Open-market sale of common stock on March 23, 2026

Weighted average sale price $19.17 per share Average price for 2,577 shares sold

Post-transaction holdings 108,758 shares Common stock directly held after the sale

Sale price range $18.99–$19.35 per share Range of individual trade prices within the reported sale

Net insider share change -2,577 shares Net sell direction in transaction summary

Key Terms

Rule 10b5-1 (c) trading plan, weighted average price, open-market sale, non-derivative

4 terms

Rule 10b5-1 (c) trading plan regulatory

"The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted..."

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

non-derivative financial

""transaction_type": "non-derivative""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Foster Karen A.

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WASHINGTON 98021

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Quality and Operations

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/23/2026		S(1)		2,577	D	$19.17(2)	108,758	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 12-04-2025

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.99 to $19.35, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

	/s/ Karen A. Foster	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did BioLife Solutions (BLFS) executive Karen A. Foster do in this Form 4?

Karen A. Foster, Chief Quality and Operations at BioLife Solutions, sold 2,577 shares of common stock. The transaction was an open-market sale at a weighted average price of $19.17 per share, reported as a routine insider trading disclosure.

How many BioLife Solutions (BLFS) shares does Karen A. Foster hold after the sale?

After the reported sale, Karen A. Foster directly holds 108,758 BioLife Solutions common shares. This post-transaction ownership figure is disclosed in the Form 4 and shows she retains a substantial continuing equity position in the company following the March 23, 2026 trade.

Was the BioLife Solutions (BLFS) insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the sales were effected under a Rule 10b5-1(c) trading plan adopted by Karen A. Foster, effective December 4, 2025. Such pre-arranged plans automate trades over time and can reduce the significance of trade timing for investor interpretation.

What price range did Karen A. Foster’s BioLife Solutions (BLFS) share sales cover?

The reported weighted average sale price was $19.17 per share. Footnotes explain the 2,577 shares were actually sold in multiple transactions at prices ranging from $18.99 to $19.35, with detailed trade-by-trade data available upon request.

What type of transaction is reported in this BioLife Solutions (BLFS) Form 4?

The Form 4 reports a non-derivative open-market sale of common stock, coded “S” for sale. It does not involve options or other derivatives, and no derivative positions are listed as remaining in the derivative summary of the filing.